The role of neurotrophins in psychopathology and cardiovascular diseases: psychosomatic connections

Andrea László1,2 · Lilla Lénárt3,4 · Lilla Illésy3 · Andrea Fekete2,4 · János Nemcsik1,5

Received: 12 October 2018 / Accepted: 16 January 2019 / Published online: 14 February 2019
© The Author(s) 2019

Abstract
Cardiovascular (CV) diseases and mood disorders are common public health problems worldwide. Their connections are widely studied, and the role of neurotrophins (NTs) is already supposed in both conditions. However, data in the literature of clinical aspects are sometimes controversial and no reviews are available describing possible associations between CV risk and mood disorders based on NTs. The mostly studied NT is brain-derived neurotrophic factor (BDNF). Decreased level of BDNF is observed in depression and its connection to hypertension has also been demonstrated with affecting the arterial baroreceptors, renin–angiotensin system and endothelial nitric oxide synthase. BDNF was also found to be the predictor of CV outcome in different patient populations. Other types of human NT-s, such as nerve growth factor, neurotrophin 3 and neurotrophin 4 also seem to have both psychopathological and CV connections. Our aim was to overview the present knowledge in this area, demonstrating a new aspect of the associations between mood disorders and CV diseases through the mediation of NTs. These findings might enlighten new psychosomatic connections and suggest new therapeutic targets that are beneficial both in respect of mood disorders and CV pathology.

Keywords Neurotrophic factors · Mood disorders · Cardiovascular diseases · Psychosomatic connections

Introduction
Neurotrophic factors or neurotrophins (NTs) consist a family of trophic factors of secreted proteins that promote growth, survival and differentiation of neurons both in the central and peripheral nervous system (Chao et al. 2006). The members of the NT family are structurally similar proteins (Keefe et al. 2017), and in mammals comprise the following four types: brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4) (Skaper 2008). The biological effects of mature NTs are mediated through the activation of one or more of the three tyrosine kinase receptors: tropomyosin receptor kinase A, -B, -C (TrkA, TrkB, TrkC). Nevertheless, NTs are synthesized from proneurotrophins, which are proteolytically cleaved to mature NTs. Proneurotrophins preferentially activate p75 neurotrophin receptor (p75Ntr) (Skaper 2008) and mainly induce apoptotic processes. The proneurotrophin cleavage seems to be an important factor, as the two classes of receptors (Trks and p75Ntr) interestingly act antagonistically on many physiological functions (Tsai 2017).

Both transcriptional and posttranslational mechanisms are involved in upstream regulation of neurotrophins. Neurotrophins’ gene structure is very complex, contains several coding and non-coding exons with multiple promoters and various spliced variants have also been reported. Human BDNF, for example, has a very complex gene structure, including 11 non-coding exons that are spliced independently to form a coding exon, thus more than 15 mRNA transcripts can be produced (Pruunsild et al. 2007). There are several cis and trans-acting transcriptional elements as well, which regulate the promoters of neurotrophins, contributing to various...
productions of neurotrophins. In neurons, cAMP response element binding protein (CREB) is one of the major transcription factors and an important regulator of neurotrophins’ gene expression.

Other studies demonstrated that various neurotransmitters, hormones and other neurotrophins also contribute to the transcriptional regulation of neurotrophins, but the molecular components involved in this regulation have not been clarified yet (Lindholm et al. 1994). Glutamate and acetylcholine up-regulate NGF and BDNF mRNA expression, while GABA down-regulates the levels of NGF and BDNF (Zafra et al. 1990, 1991). The regulation of NT-3 production is independent of cholinergic neuronal activity (da Penha Berzaghi et al. 1993).

Posttranslational modifications are also important processes regulating the productions of neurotrophins. Recently, a direct link between sigma-1 receptor (S1R) and BDNF has been discovered. Some studies described that S1R agonists (endogen like dehydroepiandrosterone or exogenous like SSRI fluvoxamine) increase BDNF expression and activate its downstream signaling. Others demonstrated that S1R acting as a chaperone protein enhances secretion of mature BDNF (Fujimoto et al. 2012). Our group also showed that S1R agonism by the fluvoxamine increases BDNF secretion in the rat hippocampus (Lenart et al. 2016).

Cardiovascular (CV) diseases are the leading cause of morbidity and mortality in most industrialized countries worldwide, despite highly effective preventive treatments. As CV diseases exert an excessive public health burden, exploring new pathophysiological pathways with the hope of new preventive and therapeutic potential can have an outmost importance. One of these new possibilities could be the involvement of NTs, which exert diverse effects on the developing and mature CV system. Their expression continues throughout life, influencing hypertension, atherosclerosis, diabetes and myocardial ischemia (Emanuelli et al. 2014).

Mood disorders are also common public health problems in the Western world and their strong connection with CV diseases is broadly recognized (Penninx et al. 2001). Lower NT concentrations, such as serum BDNF and NGF have been shown to correlate negatively with many affective disorders including bipolar disorder (Barbosa et al. 2014; Lin et al. 2014), major depressive disorder (Brunoni et al. 2008), mania (Tramontina et al. 2009) and obsessive compulsive disorder (Maina et al. 2010). Although NTs themselves do not control mood directly, they are fundamental in the activity-dependent modulation of networks and changes in plasticity can affect mood as well (Castren et al. 2007).

As NTs can cross the blood–brain barrier, they potentially can influence CV pathology and psychopathology at the same time. BDNF is not only able to cross the blood–brain barrier (Pan et al. 1998), but in the periphery it is stored in platelets as well (Karege et al. 2002). Interestingly, while BDNF and NT-3 (as well as NT-4) are both structurally and functionally related to NGF (Maness et al. 1994; Sariola et al. 1994), the permeability coefficient-surface area of NGF is much lower compared with other NTs (Poduslo and Curran 1996).

Our aims are to overview the changes of NTs in psychiatric conditions and in CV diseases to demonstrate a new area of psychosomatic connections. We also aim to review the present knowledge about the therapeutic possibilities to restore the level of NTs and their consequences for different outcomes.

Brain-derived neurotrophic factor (BDNF)

BDNF is the most frequently studied NT. It is initially synthesized in the endoplasmic reticulum as its precursor protein, preproBDNF. After the cleavage of the signal peptide this form becomes proBDNF, and proBDNF is converted by extracellular proteases to mature BDNF (Ethell and Ethell 2007; Yoshida et al. 2012).

Mature BDNF binds with higher-affinity Trk family receptors (Villanueva 2013)—especially TrkB—increasing cell survival and differentiation, dendritic spine complexity, long-term potentiation (Lu et al. 2008; Messaoudi et al. 2002), synaptic plasticity (Kang and Schuman 1996), and the rescupting of neuronal networks (Lee et al. 2001). ProBDNF is also biologically active, it mediates its actions through binding to low-affinity p75NTR, having antagonistic effect compared to mature BDNF: reducing spine complexity and density (Zagrebelsky et al. 2005) and promoting neuronal cell death (Teng et al. 2005).

BDNF in mood disorders

Numerous clinical studies confirm the involvement of BDNF in the pathophysiology of depression (Lee and Kim 2010). Reductions in serum and plasma mature BDNF have been demonstrated in patients suffering from depression (Lee et al. 2007; Yoshida et al. 2012) and in those who committed suicide (Birkenhager et al. 2012; Kim et al. 2007b). Significantly lower levels of serum BDNF were found in antidepressant-free patients with major depressive disorder compared with healthy controls (Shimizu et al. 2003), which findings were confirmed by a large cohort study (Molendijk et al. 2011) and by three meta-analyses as well (Bocchio-Chiavetto et al. 2010; Brunoni et al. 2008; Sen et al. 2008).

The regulatory background of BDNF in psychopathology is not totally clarified yet, but epigenetic mechanisms (chromatin remodeling, DNA methylation) have been implicated. Both in schizophrenia and in depression at the promoter I of BDNF DNA methylation at a specific CpG site is increased.
resulting in reduced BDNF gene transcription (Fuchikami et al. 2011; Ikegame et al. 2013).

Single nucleotide polymorphism in BDNF gene is a plausible candidate to be associated with the development of psychopathology. The Val66Met polymorphism is characterized by an amino acid substitution of valine (Val) to methionine (Met) at amino acid residue 66. The presence of Met allele causes a failure in intracellular trafficking and packaging of proBDNF, which results in a 25% reduction of the activity-dependent secretion of mature BDNF (Egan et al. 2003). However, the role of Val66Met polymorphism in psychiatric disorders is well studied but the results are inconsistent. Some studies reported that Met/Met patients have more severe symptoms of depression (Czira et al. 2012), whereas others showed that Val/Val genotype is associated with increased depressive symptoms (Jiang et al. 2013) or higher scores on the cognitive–affective factor of the Beck Depression Inventory-II test (Duncan et al. 2009).

**BDNF and CV patholgy**

BDNF plays an important role during development of the CV system: it activates TrkB receptor leading to the survival of endothelial cells and the formation of the cardiac vasculature (Emanuelli et al. 2014). Embryonic BDNF deficiency impairs the development of intramyocardial vessels and can also lead to cardiac hypercontractility (Donovan et al. 2000). BDNF functions as an angiogenic regulator, promoting angiogenesis (Kermani et al. 2005). It is expressed in a greater amount in the peripheral vessels, where it could influence vasoreactivity (Prigent-Tessier et al. 2013). BDNF is able to enhance vascular flow and can regulate revascularization of ischemic tissues (Kermani et al. 2005). Furthermore, it improves left-ventricular function in ischemic myocardium (Liu et al. 2006).

In CVD, the role of Val66Met polymorphism is still unclear, but interestingly in a follow-up clinical study patients carrying Met allele were associated with a reduced risk of clinical CVD events and lower severity of coronary artery disease than Val/Val genotype (Jiang et al. 2017). However, further investigations are needed to clarify the genetic aspect of the link between BDNF and CVD.

How can BDNF influence blood pressure, potentially playing an important role in the development of hypertension? Axonal guidance is among the top pathways explaining the association between mood disorders and cardiometabolic-disease risk (Amare et al. 2017). Mutant axonal guidance genes—including BDNF—followed by abnormal axonal guidance and connectivity can cause disorders primarily in the brain and subsequently in peripheral organs (Sasaki et al. 2014). During embryonic development, BDNF is found to be a target-derived survival factor for a large subset of nodose ganglion neurons, such as arterial baroreceptors (Brady et al. 1999) and is also involved in the development of chemoaферent sensory neurons innervating the carotid body (Conover et al. 1995; Erickson et al. 1996). Furthermore, postnatally BDNF is expressed by the nodose ganglion neurons themselves (Schecterson and Bothwell 1992; Wetmore and Olson 1995) and can be also released from these neurons by activity (Balkowiec and Katz 2000). BDNF is expressed in arterial baroreceptors and their central terminals in medial nucleus tractus solitarius in vivo. BDNF release from cultured nodose ganglion neurons is increased by electrical stimulation with patterns that mimic the in vivo activity of baroreceptor afferents (Martin et al. 2009). Thus, it seems that BDNF is involved not only in the development of baroreceptors, but also in their normal functioning in adulthood.

During normal conditions when blood pressure increases, the activated baroreflex reduces heart rate and blood pressure by a negative feedback loop. In addition, elevated blood pressure activates inhibitory GABAergic neurons in the hypothalamus, reducing the secretion of the blood pressure-elevating hormone vasopressin (Marosi and Mattson 2015). But different pathophysiological changes can influence the mechanism of the baroreflex loop. It is already shown that high dietary salt intake can affect blood pressure through NT-mediated changes of the central homeostatic circuit. Choe et al. proved in an animal study that chronic high salt intake is able to decrease the baroreceptor-mediated inhibition of vasopressin neurons through a BDNF-dependent activation of TrkB receptors and through the downregulation of potassium/chloride co-transporter 2 expression, which prevents inhibitory of GABAergic signaling (Choe et al. 2015). Furthermore, reduced BDNF level in mice results in elevated heart rate, and infusion of this NT into the cerebral ventricles can restore this effect (Wan et al. 2014). In the same study, Wan et al. showed that GABAergic responses are increased in brainstem cardiovagal neurons of BDNF+/− mice, suggesting that BDNF increases the activity of the parasympathetic neurons to reduce heart rate (Wan et al. 2014). In summary, BDNF is required for normal carotid body innervation, baroreceptor function and heart rate regulation and these effects can be blunted in pathological conditions, such as high salt intake, which can lead to the development of hypertension.

Another pathway explaining the association between BDNF, CV function and susceptibility to mental diseases as well is the renin–angiotensin system (RAS). Increased central RAS activation is an indicator of many CV diseases, such as hypertension and heart failure (Biancardi et al. 2014; Zucker et al. 2012). On the other hand, data are accumulating about the newly discovered effects of the RAS related to neuroprotection, cognition and cerebral vasodilation. Angiotensin (AT) 1–7 also affects non-CV functions in the brain, such as learning, memory, and neuroprotection (Farag et al. 2011; Ikegame et al. 2013).
Clinical studies have shown that AT II receptor type 1 (AT1R) blockers— independent of blood pressure-lowering effect—improve cognitive function in elderly hypertensive patients (Fogari et al. 2003; Hajjar et al. 2005). The background mechanism of this phenomenon was investigated in animal studies. Goel et al. showed the evidence that chronic neuroinflammation and memory impairment in hypertension—associated with increased apoptotic cell death and with amyloid beta deposition—can be prevented with candesartan treatment, suggesting partly to be explained by an increase of BDNF/CREB (cAMP response element binding protein) expression (Goel et al. 2017). Furthermore, the connection between RAS and TrkB signaling is proven in vitro (Becker et al. 2015) and in vivo as well, as Becker et al. demonstrated the mediator role of BDNF-TrkB signaling on Ang II-induced mean blood pressure and renal sympathetic nerve activity elevation in male rats (Becker et al. 2017). Thus probably RAS blockers restore BDNF through TrkB signaling pathway.

Cumulating data suggest the connection between endothelial dysfunction and BDNF as well. In an animal study, the protecting effect of the AT1R blocker candesartan after stroke was mediated by endothelial nitric oxide (NO) synthase and it was positively associated with BDNF expression (Alhusban et al. 2017). BDNF is probably indirectly associated with the NO-system as BDNF is secreted by endothelial cells (Zoladz and Pilc 2010), it increases vascular endothelial growth factor (VEGF) expression, which induces angiogenesis (Chen et al. 2005a; Lin et al. 2014) and VEGF also enhances the NO production of endothelial cells (Youn et al. 2009). The connection with endothelial dysfunction is also supported by the observation, that circulating BDNF level inversely correlates with vascular cell adhesion molecule-1 (Lee et al. 2012), which is an accepted biomarker of endothelial dysfunction (Burger and Touyz 2012).

Numerous data are available about the association between BDNF and CV health. In general population, a significant positive correlation was observed between plasma BDNF and diastolic blood pressure, and sexual differences were demonstrated in relation with different serum lipids (Golden et al. 2010). As it was a cross-sectional study, it is unclear if these associations observed are casual or elevated plasma BDNF represents a compensatory response of the disrupted lipid metabolism and hypertension, but the elevation of serum BDNF in hypertension was confirmed by our study as well (Nemcsik et al. 2016). Interestingly, in contrast, decreased endothelial BDNF expression was found in hypertension (Prigent-Tessier et al. 2013), so the source of higher BDNF serum and plasma levels in hypertension is probably not the endothelial cells. Increased BDNF expression was found in atherosclerotic coronary arteries in humans (Ejiri et al. 2005), and decreased plasma BDNF level was observed in patients with metabolic syndrome (Chaldakov et al. 2004), acute coronary syndrome (Lorig et al. 2010; Manni et al. 2005) and in type 2 diabetes mellitus (Krabbe et al. 2007).

About obesity we found contradictory results in the literature. Previous studies showed that serum BDNF is generally lower in overweight and obese subjects (Celik Guzel et al. 2014; Corripio et al. 2012; El-Gharbawy et al. 2006). In contrary, others showed elevated serum BDNF level in obesity (Roth et al. 2013). This phenomenon has been explained by the fact that BDNF is also regulated by leptin, therefore leptin resistance—as one of the obesity-associated factors—shall be considered in future studies.

Serum BDNF level was diminished in smokers, compared to non-smokers (Bhang et al. 2010; Kim et al. 2007a). Furthermore, BDNF levels in chronic smokers were increased after smoking cessation (30).

In patients with angina pectoris Jiang at al. found that plasma BDNF was inversely associated with triglyceride and low-density lipoprotein (LDL)-cholesterol, male sex and age, while it was correlated positively with high-density lipoprotein (HDL)-cholesterol. In this cohort, low plasma BDNF was an independent predictor of future coronary events and mortality (Jiang et al. 2011). The predictive role of BDNF for future CV events and mortality was confirmed by other studies as well. Higher seBDNF was found to be associated with decreased risk of CV morbidity and mortality (Kaess et al. 2015). On contrary, decreased serum BDNF was found to be associated with increased risk of incident stroke/TIA (Pikula et al. 2013). In summary, these results suggest that BDNF is compensatory elevated in CV pathology and the lack of this elevation bears propensity for poor outcome.

**Direct psychosomatic connections of BDNF**

Only a few studies are available evaluating the role of BDNF both in vascular and psychiatric conditions. Affective temperament types (depressive, cyclothymic, hyperthymic, irritable and anxious) are subclinical, trait-related manifestations and commonly the antecedents of minor and major mood disorders (Rihmer et al. 2010). We previously demonstrated that in chronic hypertensive patients with dominant irritable, anxious, cyclothymic and depressive affective temperaments, serum BDNF level was decreased compared with chronic hypertensive patients without dominant affective temperaments (Laszlo et al. 2015). In chronic hypertensive patients, hyperthymic temperament score was found to be associated positively with serum BDNF level (Nemcsik et al. 2016). As hyperthymic temperament score was found to be inversely associated with coronary atherosclerosis (Nemcsik et al. 2017), it can be proposed that BDNF is a mediator of the protective effect of hyperthymic temperament in CV conditions. But in hypertension the elevation of BDNF can also be an effect of medications as in a preliminary study after...
3 months of antihypertensive therapy a tendency of BDNF increase was observed (Korosi et al. 2017). In this cohort, almost all patients did get the ACE-inhibitor perindopril, which, although only in the brain, but was demonstrated to influence BDNF (Ali et al. 2016).

Opportunities to restore BDNF level

Considering that BDNF is involved in CV physiology and through enhancing the neuroplasticity and neurogenesis, it increases the resistance of neurons to metabolic and exotoxic stress (Marosi and Mattson 2014) a new therapeutic target of mood and CV disorders could be the restoration of BDNF level.

Lifestyle changes like physical activity, such as running and other types of aerobic exercise (Engesser-Cesar et al. 2007; Griffin et al. 2011) or calorie restriction (Marosi and Mattson 2014) could be cardioprotective through BDNF mediation.

Long-term treatment with various antidepressants can also normalize serum BDNF level (Duman and Monteggia 2006; Sen et al. 2008). In animal studies, antidepressants, including selective serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors, and monoamine oxidase inhibitors elevate BDNF mRNA level in hippocampus (Huang et al. 2008). In psychiatry practice, BDNF level improvement can be evoked not only through medication, but also through electroconvulsive therapy (Brunoni et al. 2014). In relation with the CV pharmacology, the AT1R blocker candesartan is proven to restore BDNF (Alhusban et al. 2017) and the ACE-inhibitor perindopril has beneficial effects as well (Ali et al. 2016), but interestingly in case of ramipril this feature seems to be missing (Krikov et al. 2008). As we previously mentioned, RAS blockers probably restore BDNF through TrkB signaling pathway.

In the future, a possibility of BDNF restoration could be the inhibition of its degradation. The mechanism of BDNF degradation is not well investigated, in the literature there are only few studies about this process. More than 25% of synthesized BDNF is deperedated by lysosomes. Soluble sortilin is a main protein, which directs the trafficking of BDNF. Sortilin binds to sorting motif of BDNF and facilitates BDNF allocation to the late endosome; hereby sortilin rescues BDNF from lysosomal degradation. Until now no pharmacological option exists to inhibit the degradation of BDNF. Modifying sortilin either with increasing its level or its binding action would be options to increase total BDNF levels through its decreased targeting to the lysosome (Evans et al. 2011).

As there is no agent that would reduce BDNF degradation, direct receptor (TrkB) activation via ligands/agonists or mechanisms of increasing the BDNF level would be also appropriate therapeutic applications. Based on the listed psychopathological and CV effects of BDNF, such a medication can potentially be beneficial for both systems.

Nerve growth factor (NGF)

NGF is another important member of the NT family, produced mainly in the cortex, hippocampus, hypothalamus, but—like BDNF—it is also found in peripheral nervous and immune systems (Wiener et al. 2015). The adrenal gland also appears to be an important biological target of NGF (Alleva et al. 1993; Aloe et al. 1986), thus it could represent an intermediate station in the communication between central nervous system structures and peripheral organs (Cirulli and Alleva 2009). The mature, active form of NGF descends from proteolytic cleavage of a precursor form proNGF, which also has important roles during development and in adult life, having both pro-apoptotic and neurotrophic properties (Fahnestock et al. 2004a, b). The biological action of NGF is mediated by two receptors: the high-affinity receptor TrkA, and the low-affinity transmembrane glycoprotein receptor p75, that regulates signaling through TrkA (Huang and Reichardt 2003). Binding of NGF to p75Ntr activates additional signaling pathways: in the absence or reduced expression of coexpressed TrkA receptors on NGF-target cell apoptosis is triggered by NGF (Ebendal 1992; Huang and Reichardt 2003). Therefore, the effect of NGF on target cells depends on the ratio of these two receptors co-distributed on the cell surface (Micera et al. 2007).

NGF in mood disorders

Like BDNF, NGF seems to be negatively associated with depression and suicide. Clinical studies showed reduced level of NGF in patients with major depressive disorder compared with healthy controls (Diniz et al. 2013; Xiong et al. 2011), and a study with suicide victims showed also decreased NGF in the hippocampus (Banerjee et al. 2013). Comparing patients with major depressive disorder to such with major depressive disorder and additional suicide risk, Wiener et al. found no differences in NGF levels, but differences were found when comparing them to healthy controls (Wiener et al. 2015). Similarly, Dwivedi et al. found differences of NGF levels in the prefrontal cortex and in the hippocampus only when comparing suicide victims with major depressive disorder and additional suicide risk, Wiener et al. found no differences in NGF levels, but differences were found when comparing them to healthy controls (Wiener et al. 2015). Similarly, Dwivedi et al. found differences of NGF levels in the prefrontal cortex and in the hippocampus only when comparing suicide victims with major depressive disorder and suicide victims with other psychiatric disorders to healthy controls, but not when comparing the two analyzed groups to each other (Dwivedi et al. 2005). On the contrary, in an elderly population, Ziegenhorn et al. did not confirm the influence of depression on serum NGF level (Ziegenhorn et al. 2007). Thus, it seems that NGF has an important role in the pathophysiology of mood disorders, but with aging this association can be attenuated.
NGF and CV pathology

Additionally to neural growth effects, NGF was the first NT found to be involved in the postnatal angiogenesis with the mediation of TrkA receptors (Emanuelli et al. 2014)—although the mechanism of the angiogenic effects of NGF is not totally clarified yet. It is mediated either by a direct effect on vascular endothelial cells, or indirectly by influencing the action of other endogenous growth factors, for example, VEGF (Han et al. 2008; Nico et al. 2008). Asanome et al. showed in an animal study that the effects of NGF on vascular maturation are mediated through perivascular nerves (Asanome et al. 2014). Among other NTs, the expressions of NGF and TrkA are both dramatically upregulated by arterial balloon injury in rats and during neointima formation their increased levels are maintained (Emanuelli et al. 2014).

It is known since the 90s that in spontaneously hypertensive rats the NGF secretion in the vessels is elevated (Spitsbergen et al. 1998; Tuttle et al. 1995; Zettler and Rush 1993). It is associated with sympathetic hyperinnervation (Head 1989; Spitsbergen et al. 1998), which seems to be mediated by altered signaling of vascular smooth muscle cells (Tuttle et al. 1995). Further studies also implicated increased expression of NGF in the vascular system as causing the development of sympathetic hyperinnervation resulting in hypertension (Emanuelli et al. 2014). On the other hand, the activation of TrkA by NGF is also required for survival of the sympathetic and sensory neurons that innervate the heart (Emanuelli et al. 2014). NGF can protect against post-ischemic dysfunction of sympathetic coronary innervation (Abe et al. 1997) and ischemia–reperfusion-induced myocardial injury in animal studies (Hiltunen et al. 2001). Therefore, it seems that in animal models NGF provides Janus-faced features mediating in one way the development of hypertension, and on the other hand, protecting against ischemia-induced injuries.

Recent human studies have reported that NGF has importance in atherosclerosis and related disorders (Chaldakov et al. 2004; Donovan et al. 1995). NGF level in advanced atherosclerosis of the coronary wall was significantly lower than in controls and plasma level of NGF was reduced in patients with metabolic syndrome compared with controls (Chaldakov et al. 2004). One of the possible ways for explaining the role of NGF in metabolic disorders is the fact that NGF upregulates the expression of LDL receptor-related protein, which leads to a decreased level of LDL, and subsequently a lower probability of atherosclerosis (Bu et al. 1998). Another explanation is that NGF shares a striking structural homology with proinsulin (Mukherjee and Mukherjee 1982), increases glucose-induced insulin secretion (Hiriart et al. 2001) and exerts certain insulin-like effects on lipid metabolism (Mukherjee and Mukherjee 1982; Ng and Wong 1985) and on energy homeostasis (Salton 2003). Taken together, the fact that plasma NGF level is reduced in chronic (Chaldakov et al. 2004) as well as in acute stages of human coronary atherosclerosis (Manni et al. 2005), suggests the role of NT deficiency in the pathophysiology of atherosclerosis and the association of NGF with CV diseases (Manni et al. 2005).

Direct psychosomatic evidences of NGF

No human study is available evaluating both psychopathological and CV disease conditions in relation with the role of NGF. The administration of NGF in eye-drops in streptozotocin-induced diabetic rats was proven to recover brain damage in the prefrontal cortex by activating protective and remodeling pathways triggered by BDNF. The authors also suggest based on their result that NGF-induced changes in BDNF signaling might influence the manifestation of depressive phenotype in diabetic rats (Rosso et al. 2017). These results suggest that the potentially beneficial psychosomatic effects of NGF are mediated by BDNF, but future studies are required to confirm this hypothesis.

Opportunities to restore NGF level

There are data in the literature that exercise can influence NGF. In soldiers, plasma NGF level was increased following emotional excitation and physical stress (Dugue et al. 1993; Schedlowski et al. 1993), and intense and prolonged physical exercise was associated with an increased serum NGF level in athletes (Bonini et al. 2013).

The therapeutic options for normalizing NGF levels are not that well known as in case of BDNF. Certain antidepressants—such as nortriptyline and citalopram—increased NGF levels in both experimental and clinical studies (Hassanzadeh and Rahimpour 2011). On the other hand, the decreased NGF level of patients with major depressive disorder decreased further after duloxetine administration (Martino et al. 2013). Interestingly, in another study after 8 weeks of intensive administration of antidepressants, significant improvement in the clinical symptoms of mood disorders was demonstrated without changes in NGF level (Liu et al. 2014). These results suggest neutral or bidirectional response of NGF for different antidepressant agents.

Neurotrophin 3 (NT-3)

Neither NT-3 nor its proform, proNT-3 have received as much attention in the literature as BDNF or NGF and their proforms. NT-3 binds mainly to TrkC receptors, but can also interact with less efficiency with TrkA and TrkB receptors (Yano et al. 2009). Like other NTs, NT-3 has an important role in the development and maintenance of the nervous system. It stimulates and controls neurogenesis through the
activation of TrkC receptors, plays role in the regulation of monoamine neurotransmitters such as noradrenaline and serotonin and enhances other neurotrophic factors such as BDNF and NGF (Pae et al. 2008). ProNT-3 exerts controversial effects inducing cell death in superior cervical ganglion neurons through binding a complex between sortilin and p75Ntr (Gibon and Barker 2017).

**NT-3 in mood disorders**

Studies about the possible connections between NT-3 and mood disorders are still controversial. Hock et al. found increased cerebrospinal fluid levels of NT-3 in elderly patients with depression compared with mentally healthy control subjects (Hock et al. 2000), and other studies also showed increased NT-3 level in bipolar disorders (Loch et al. 2015; Tseng et al. 2016). In contrast, a study demonstrated the opposite result (Otsuki et al. 2008), while Munkholm et al. found no difference in NT-3 level in bipolar disorder patients compared with controls (Munkholm et al. 2014).

**NT-3 and CV pathology**

NT-3 through TrkC activation is required for the development of the ventricles, the atria and the cardiac outflow tracts (Donovan et al. 1996; Tessarollo et al. 1997). The lack of NT-3 leads to septal defects and Fallot tetralogy (Donovan et al. 1996).

While BDNF through TrkB activation is required for the survival of arterial baroreceptors during development (Brady et al. 1999), NT-3 is also involved in the development of chemoafferent sensory neurons innervating the carotid body (Conover et al. 1995; Erickson et al. 1996).

It is known that the NT-3 receptor TrkC is expressed in mouse skeletal muscle endothelial cells and also in human veins. Cristofaro et al. found in animal models that NT-3 has a role in the stimulation of angiogenesis in which the endothelial NO synthase pathway has a critical role both in vivo and in vitro (Cristofaro et al. 2010).

Other studies suggest various effects of NT-3. Zhang et al. found elevated NT-3 level in hypertensive rat model compared with normotensive animals (Zhang and Rush 2001). The presence of NT-3 in human arteriosclerotic lesions was also observed (Donovan et al. 1995) and this NT seems to be a profibrogenic mediator in human aortic valve: overproduction of NT-3 by aortic valve tissue may contribute to the mechanism of valvular sclerosis (Yao et al. 2017).

**Direct psychosomatic evidences of NT-3**

No animal or human study is available evaluating the role of NT-3 in psychopathology and CV pathology at the same time. As common pathophysiological pathways are present similarly like in the case of other NTs, the clarification of the possible psychosomatic role of NT-3 could be an interesting task of future studies.

**Opportunities to restore NT-3 levels**

Similar to BDNF, NT-3 level can probably be restored with exercise: in animal model physical activity increased NT-3 and TrkC expression following focal cerebral ischemia (Chung et al. 2017).

Currently, available findings suggest possible therapeutic implications of NT-3 in the treatment of depression (Pae et al. 2008). This can be explained with the fact that NT-3 is a modulator of other NT-s, such as BDNF (Schutte et al. 2000) and has a direct effect on monoamine neurotransmitters such as 5-hydroxytryptamine and noradrenaline (Celada et al. 1996; Martin-Iverson et al. 1994).

**Neurotrophin 4 (NT-4)**

Although NT-4 acts on the same TrkB receptor like BDNF, they do not invariably mediate the same effects (Hyman et al. 1994; Rodriguez Fernepin et al. 2009): BDNF elicits stronger and faster ubiquitination with TrkB than NT-4 (Proenca et al. 2016), and NT-4 has a more potent effect than BDNF in the protection on striatal dopaminergic neurons (Sauer et al. 1995). Little is known about proNT-4, but its truncated prodomain region prevents proNT-4 to bind to sortilin (Chen et al. 2005b). However, to date, its role in synaptic activity or synaptic plasticity has not been reported (Gibon and Barker 2017).

**NT-4 in mood disorders**

NT-4 promotes survival and differentiation of hippocampal (Ip et al. 1992, 1993), noradrenergic (Friedman et al. 1993) and dopaminergic (Altar et al. 1994; Hyman et al. 1994) neurons. Striatal dopaminergic neurons are believed to be one of the key neurons in the pathophysiology of bipolar disorder (Sauer et al. 1995), thus the association between mood disorders and NT-4 level is probable, but the results are controversial. Serum NT-4 was found to be elevated in patients with bipolar disorder compared with healthy controls (Tseng et al. 2016; Walz et al. 2009), however, in another study no differences were found between the two groups (Aydemir et al. 2014). Moreover, Barbosa et al. showed decreased NT-4 level in bipolar disorder with mania (Barbosa et al. 2014).

**NT-4 and CV pathology**

Similar to NT-3, NT-4 is also involved in the development of chemoafferent sensory neurons innervating the carotid
As TrkB is a mediator of the long-term blood pressure and sympathetic nerve activity responses to central angiotensin II activity (Becker et al. 2017), NT-4—binding the same TrkB-receptor—might have similar functions, even if the role of NT4/TrkB signaling in sympathetic control of blood pressure is still even less precisely understood than BDNF/TrkB signaling.

**Direct psychosomatic evidences of NT-4**

Similarly like NT-3, no animal or human studies are available evaluating the role of NT-4 in psychopathology and CV pathology at the same time. As NT-4 acts also on
TrkB-receptor it might show similarities with the effects of BDNF, but the clarification of its exact role needs further studies.

**Opportunities to restore NT-4 levels**

Little is known about the effect of different medications on NT-4 level. In a study of Loch et al. in patients with bipolar disorder after the administration of lithium, NT-4 level did not change (Loch et al. 2015). Apart from these results, no data are available in the literature about the possibilities of NT-4 level modification and its physiological consequences.

**Conclusions**

The accumulating data about the role of NTs, especially BDNF both in psychopathology and CV diseases, suggest that besides the involvement of the hypothalamic–pituitary–adrenal axis and the autonomic nervous system, NT pathway can also mediate psychosomatic processes. Its physiological background is based on the shared signaling pathways descending from Trk receptors and p75Ntr to both psychopathological and CV directions. The summary of our knowledge in this field, which was detailed above in this manuscript is demonstrated in Fig. 1.

However, much more studies are needed, not only observational, but also interventional ones evaluating in psychopathological and CV conditions at the same time aiming to discover the mediator role of NTs to confirm this hypothesis, but in case of supportive results, new therapeutic targets can be defined with the possibility of beneficial effects on two groups of diseases with huge public health impact.

**Acknowledgements** Open access funding provided by Semmelweis University (SE). Andrea Fekete and Lilla Lénárt were supported by the following research grants: OTKA-K112629-FK124491, NN-11460, VKE-2017-00006, EEMOFAKT-2017 and the ‘Momentum’ Program of the Hungarian Academy of Sciences LP008/2017. However, these grants had no influence for the content of this review paper.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

Abe T, Morgan DA, Guterman DD (1997) Protective role of nerve growth factor against postischemic dysfunction of sympathetic coronary innervation. Circulation 95:213–220

Alhusban A et al (2017) Mechanisms of acute neurovascular protection with AT1 blockade after stroke: effect of prestroke hypertension. PLoS One 12:e0178867. https://doi.org/10.1371/journal.pone.0178867

Ali MR, Abo-Youssef AM, Messiha BA, Khattab MM (2016) Tempol and perindopril protect against lipopolysaccharide-induced cognition impairment and amyloidogenesis by modulating brain-derived neurotropic factor, neuroinflammation and oxido-nitrosative stress. Naunyn Schmiedeberg’s Arch Pharmacol 389:637–656. https://doi.org/10.1007/s00210-016-1234-6

Alleva E, Aloe L, Bigi S (1993) An updated role for nerve growth factor in neurobehavioural regulation of adult vertebrates. Rev Neurosci 4:41–62

Aloe L, Alleva E, Bohm A, Levi-Montalcini R (1986) Aggressive behavior induces release of nerve growth factor from mouse salivary gland into the bloodstream. Proc Natl Acad Sci USA 83:6184–6187

Altar CA, Boylan CB, Fritsche M, Jackson C, Hyman C, Lindsay RM (1994) The neurotrophins NT-4/5 and BDNF augment serotonin, dopamine, and GABAergic systems during behaviorally effective infusions to the substantia nigra. Exp Neurol 130:31–40. https://doi.org/10.1006/exnr.1994.1182

Amare AT, Schubert KO, Klingler-Hoffmann M, Cohen-Woods S, Baune BT (2017) The genetic overlap between mood disorders and cardiometabolic diseases: a systematic review of genome wide and candidate gene studies. Transl Psychiatry 7:e1007. https://doi.org/10.1038/tp.2016.261

Asanome A et al (2014) Nerve growth factor stimulates regeneration of perivascular nerve, and induces the maturation of microvessels around the injured artery. Biochem Biophys Res Commun 443:150–155. https://doi.org/10.1016/j.bbrc.2013.11.070

Aydemir O, Cubukcuoglu Z, Erdin S, Tas C, Onur E, Berk M (2014) Oxidative stress markers, cognitive functions, and psychosocial functioning in bipolar disorder: an empirical cross-sectional study. Rev Bras Psiquiatr 36:293–297. https://doi.org/10.1590/1516-4446-2013-1299

Balkowiec A, Katz DM (2000) Activity-dependent release of endogenous brain-derived neurotrophic factor from primary sensory neurons detected by ELISA in situ. J Neurosci 20:7417–7423

Banerjee R, Ghosh AK, Ghosh B, Bhattacharyya S, Mondal AC (2013) Decreased mRNA and protein expression of BDNF, NGF, and their receptors in the hippocampus from suicide: an analysis in human postmortem. Brain Clin Med Insights Pathol 6:1–11. https://doi.org/10.4137/CMPat h.S12530

Barbosa IG, Morato IB, Huguet RB, Rocha FL, Machado-Vieira R, Teixeira AL (2014) Decreased plasma neurotrophin-4/5 levels in bipolar disorder patients in mania. Rev Bras Psiquiatr 36:340–343. https://doi.org/10.1590/1516-4446-2014-1380

Becker BK, Wang HJ, Tian C, Zucker IH (2015) BDNF contributes to angiotensin II-mediated reductions in peak voltage-gated K+ current in cultured CATH.a cells. Physiol Rep. https://doi.org/10.14814/phy2.12598

Becker BK, Wang H, Zucker IH (2017) Central TrkB blockade attenuates ICV angiotensin II-hypertension and sympathetic nerve activity in male Sprague-Dawley rats. Auton Neurosci 205:77–86. https://doi.org/10.1016/j.autneu.2017.05.009

Bhang SY, Choi SW, Ahn JH (2010) Changes in plasma brain-derived neurotrophic factor levels in smokers after smoking cessation. Neurosci Lett 468:7–11. https://doi.org/10.1016/j.neulet.2009.10.046

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Biancardi VC, Son SJ, Ahmadi S, Filosa JA, Stern JE (2014) Circulating angiotensin II gains access to the hypothalamus and brain stem during hypertension via breakdown of the blood–brain barrier. Hypertension 63:572–579. https://doi.org/10.1161/HYPERTENSIONAHA.113.01743

Birkenhager TK, Geldermans S, Van den Broek WW, van Beveren N, Fekkes D (2012) Serum brain-derived neurotrophic factor level in relation to illness severity and episode duration in patients with major depression. J Psychiatr Res 46:285–289. https://doi.org/10.1016/j.jpsychires.2011.12.006

Bocchio-Chiavetto L et al (2010) Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry 11:763–773. https://doi.org/10.3109/15622975.2011.5661319

Bonini M, Fioretti D, Sargentini V, Del Giacco S, Rinaldi M, Tranquilli C, Bonini S (2013) Increased nerve growth factor serum levels in top athletes. Clin J Sport Med 23:228–231. https://doi.org/10.1097/01.JS.00004318276e6d5

Brady R, Zaidi SI, Mayer C, Katz DM (1999) BDNF is a target-derived survival factor for arterial baroreceptor and chemoafferent primary sensory neurons. J Neurosci 19:2131–2142

Brunoni AR, Lopes M, Fregni F (2008) A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 11:1169–1180. https://doi.org/10.1016/j.ijnp.2007.11.006

Brunoni AR, Baeken C, Machado-Vieira R, Gattaz WF, Vanderhasseit MA (2014) BDNF blood levels after electroconvulsive therapy in patients with mood disorders: a systematic review and meta-analysis. World J Biol Psychiatry 15:411–418. https://doi.org/10.3109/15622975.2014.892633

Bu G, Sun Y, Schwartz AL, Holtzman DM (1998) Nerve growth factor induces rapid increases in functional cell surface low density lipoprotein receptor-related protein. J Biol Chem 273:13359–13365

Burger D, Touyz RM (2012) Cellular biomarkers of endothelial health: microparticles, endothelial progenitor cells, and circulating endothelial cells. J Am Soc Hypertens 6:85–99. https://doi.org/10.1016/j.jsh.2011.11.003

Castren E, Voikar V, Rantamaki T (2007) Role of neurotrophic factors in depression. Curr Opin Pharmacol 7:18–21. https://doi.org/10.1016/j.coph.2006.08.009

Celada P, Siuciak JA, Tran TM, Altar CA, Tepper JM (1996) Local infusion of brain-derived neurotrophic factor modifies the firing pattern of dorsal raphe serotonergic neurons. Brain Res 712:293–298

Celik Guzel E, Bakkal E, Guzel S, Eroglu HE, Acar A, Kucukyalcin V, Topcu B (2014) Can low brain-derived neurotrophic factor levels be a marker of the presence of depression in obese women? Neuropsychiatr Dis Treat 10:2079–2086. https://doi.org/10.2147/NNDT.S72087

Chaldakov GN et al (2004) Neurotrophin presence in human coronary microvascular endothelial cells. J Mol Cell Cardiol 36:555–561

Chaloupka GC et al (2004) BDNF in vivo in human coronary microvascular endothelial cells. J Mol Cell Cardiol 36:555–561

Choe KY et al (2015) High salt intake increases blood pressure via BDNF-mediated downregulation of KCC2 and impaired baroreflex inhibition of vasopressin neurons. Neuron 85:549–560. https://doi.org/10.1016/j.neuron.2014.12.048

Chung JY, Kim MW, Im W, Hwang IK, Bang MS, Kim M (2017) Expression of neurotrophin-3 and trkC following focal cerebral ischemia in adult rat brain with treadmill exercise. Biomed Res Int 2017:9248542. https://doi.org/10.1155/2017/9248542

Cirulli F, Alleva E (2009) The NGF saga: from animal models of psychosocial stress to stress-related psychopathology. Front Neuroendocrinol 30:379–395. https://doi.org/10.1016/j.yfrne.2009.05.002

Conover JC et al (1995) Neuronal deficits, not involving motor neurons, in mice lacking BDNF and/or NT4. Nature 375:235–238. https://doi.org/10.1038/375235a0

Corripio R, Gonzalez-Clemente JM, Jacobo PS, Silvia N, Lluis G, Joan V, Assumpta C (2012) Plasma brain-derived neurotrophic factor in prepubertal obese children: results from a 2-year lifestyle intervention programme. Clin Endocrinol (Oxf) 77:715–720. https://doi.org/10.1111/j.1365-2265.2012.04431.x

Cristofaro B et al (2010) Neurotrophin-3 is a novel angiogenic factor capable of therapeutic neovascularization in a mouse model of limb ischemia. Arterioscler Thromb Vasc Biol 30:1143–1150. https://doi.org/10.1161/ATVBAHA.109.205468

Czira ME, Wersching H, Baune BT, Berger K (2012) Brain-derived neurotrophic factor gene polymorphisms, neurotransmitter levels, and depressive symptoms in an elderly population. Age (Dordr) 34:1529–1541. https://doi.org/10.1007/s11357-011-9313-6

da Penha Berzaghi M, Cooper J, Castren E, Zafra F, Sofroniew M, Thoenen H, Lindholm D (1993) Cholinergic regulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) but not neurotrophin-3 (NT-3) mRNA levels in the developing rat hippocampus. J Neurosci 13:3818–3826

Diniz BS, Teixeira AL, Machado-Vieira R, Talib LL, Gattaz WF, Forlenza OV (2013) Reduced serum nerve growth factor in patients with late-life depression. Am J Geriatr Psychiatry 21:493–496. https://doi.org/10.1016/j.jgp.2013.01.014

Donovan MJ et al (1995) Neurotrophin and neurotrophin receptors in vascular smooth muscle cells. Regulation of expression in response to injury. Am J Pathol 147:309–324

Donovan MJ, Hahn R, Tessarollo L, Hempstead BL (1996) Identification of an essential nonneuronal function of neurotrophin 3 in mammalian cardiac development. Nat Genet 14:210–213. https://doi.org/10.1038/nrg106-210

Donovan MJ et al (2000) Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization. Development 127:4531–4540

Dugue B, Leppanen EA, Teppo AM, Fyhruquist F, Grasbeck R (1993) Effects of psychological stress on plasma interleukins-1 beta and 6, C-reactive protein, tumour necrosis factor alpha, anti-diuretic hormone and serum cortisol Scand. J Clin Lab Invest 53:555–561

Duman RS, Monteggia LM (2006) A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59:1116–1127. https://doi.org/10.1016/j.biopsych.2006.02.013

Duncan LE, Hutchison KE, Carey G, Craighead WE (2009) Variation in brain-derived neurotrophic factor (BDNF) gene and symptoms of depression. J Affect Disord 115:215–219. https://doi.org/10.1016/j.jad.2008.08.016

Dwivedi Y, Mondal AC, Rizavi HS, Conley RR (2005) Suicide brain and peripheral markers: the role of neurotrophins. Trends Neurosci.1017-05.2005

Ebendal T (1992) Function and evolution in the NGF family and its receptors. J Neurosci Res 32:461–470. https://doi.org/10.1002/jnr.490320402
The role of neurotrophins in psychopathology and cardiovascular diseases: psychosomatic...
Brain-derived neurotrophic factor (BDNF) polymorphism is associated with disease severity and incidence of cardiovascular events in a patient cohort. Am Heart J 190:40–45. https://doi.org/10.1016/j.ahj.2017.05.002

Kang H, Schuman EM (1996) A requirement for local protein synthesis in neurotrophin-induced hippocampal synaptic plasticity. Science 273:1402–1406

Karege F, Schwald M, Cisse M (2002) Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 328:261–264

Keefe KM, Sheikh IS, Smith GM (2017) Targeting neurotrophins to specific populations of neurons: NGF, BDNF, and NT-3 and their relevance for treatment of spinal cord injury. Int J Mol Sci. https://doi.org/10.3390/ijms18030548

Kermani P et al (2005) Neurotrophins promote revascularization by local recruitment of TrkB + endothelial cells and systemic mobilization of hematopoietic progenitors. J Clin Investig 115:653–663. https://doi.org/10.1172/JCI22655

Kim TS, Kim DJ, Lee H, Kim YK (2007a) Increased plasma brain-derived neurotrophic factor levels in chronic smokers following unaided smoking cessation. Neurosci Lett 423:53–57. https://doi.org/10.1016/j.nlet.2007.05.064

Kim YK et al (2007b) Low plasma BDNF is associated with suicidal behavior in major depression. Prog Neuropsychopharmac Biol Psychiatry 31:78–85. https://doi.org/10.1016/j.pnpbp.2006.06.024

Korosi B et al (2017) The impact of currently recommended antihypertensive therapy on depression and other psychometric parameters: preliminary communication. Neuropsychopharmacologia Hungarica: a Magyar Pszichofarmakologiai Egyesulet lapja 19:11–22

Krabbe KS et al (2007) Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 50:431–438 https://doi.org/10.1007/s00125-006-0537-4

Krikov M, Thone-Reineke C, Muller S, Villringer A, Unger T (2008) Reduced plasma levels of NGF and BDNF in patients with manic episode of bipolar disorder. Psychiatry Res 218:54–60. https://doi.org/10.1016/j.psychres.2014.03.042

Loch AA et al (2015) Elevated neurotrophin-3 and neurotrophin 4/5 levels in unmedicated bipolar depression and the effects of lithium. Prog Neuropsychopharmac Biol Psychiatry 56:243–246. https://doi.org/10.1016/j.pnpbp.2014.09.014

Lorgis L et al (2010) Serum brain-derived neurotrophic factor and platelet activation evaluated by soluble P-selectin and soluble CD-40-ligand in patients with acute myocardial infarction. Fundam Clin Pharmacol 24:525–530. https://doi.org/10.1111/j.1472-8206.2009.00790.x

Lu Y, Christian K, Lu B (2008) BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol Learn Mem 89:312–323. https://doi.org/10.1016/j.nlm.2007.08.018

Manni L, Nikolova V, Vyagova D, Chaldakov GN, Aloe L (2005) Activity-dependent and hormonal regulation of neurotrophin mRNA levels in the brain—implications for neuronal plasticity. J Neurobiol 25:89–98. https://doi.org/10.1016/j.tem.2004.10.009

Messaoudi E, Ying SW, Kanhema T, Croll SD, Bramham CR (2002) Reduced plasma levels of NGF and BDNF in patients with manic episode of bipolar disorder. Psychiatry Res 101:239–244. https://doi.org/10.1016/S0165-1781(01)00318-4

Martin JL, Jenkins VK, Hsieh HY, Balkowiec A (2009) Brain-derived neurotrophic factor in arterial baroreceptor pathways: implications for activity-dependent plasticity at baroafferent synapses. J Neurochem 108:450–464. https://doi.org/10.1111/j.1471-4159.2008.05781.x

Martin-Iverson MT, Todd KG, Altar CA (1994) Brain-derived neurotrophic factor and neurotrophin-3 activate striatal dopamine and serotonin metabolism and related behaviors: interactions with amphetamine. J Neurosci 14:1262–1270

Martino M et al (2013) NGF serum levels variations in major depressed patients receiving duloxetine. Psychoneuroendocrinology 38:1824–1828. https://doi.org/10.1016/j.psyneuen.2013.02.009

Messaoudi E, Ying SW, Croll SD, Bramham CR (2002) Brain-derived neurotrophic factor triggers transcription-dependent, late phase long-term potentiation in vivo. J Neurosci 22:7453–7461

Lee BH, Kim YK (2010) The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment. Psychiatry Invest 7:231–235. https://doi.org/10.4306/pi.2010.7.4.231

Lee R, Kermani P, Teng KK, Hempstead BL (2001) Regulation of cell survival by secreted prionneurotrophs. Science 294:1945–1948. https://doi.org/10.1126/science.1065057

Lee BH, Kim H, Park SH, Kim YK (2007) Decreased plasma BDNF level in depressive patients. J Affect Disord 101:239–244. https://doi.org/10.1016/j.jad.2006.11.005

Lee IT et al (2012) Brain-derived neurotrophic factor not associated with metabolic syndrome but inversely correlated with vascular cell adhesion molecule-1 in men without diabetes. Clin Chim Acta 413:944–948. https://doi.org/10.1016/j.cca.2012.02.013

Lenart L et al (2016) The role of sigma-1 receptor and brain-derived neurotrophic factor in the development of diabetes and comorbid depression in streptozotocin-induced diabetic rats. Psychopharmacology (Berl) 233:1269–1278. https://doi.org/10.1007/s00213-016-4209-x

Lin CY, Hung SY, Chen HT, Tsou HK, Fong YC, Wang SW, Tang CH (2014) Brain-derived neurotrophic factor increases vascular endothelial growth factor expression and enhances angiogenesis in human chondrosarcoma cells. Biochem Pharmacol 91:522–533. https://doi.org/10.1016/j.bcp.2014.08.008

Lindholm D, Castren E, Berzaghi M, Blochl A, Thoenen H (1994) Activity-dependent and hormonal regulation of neurotrophin mRNA levels in the brain—implications for neuronal plasticity. J Neurobiol 25:1362–1372. https://doi.org/10.1002/neu.480251105

Liu Y, Sun L, Huan Y, Zhao H, Deng J (2006) Application of bFGF and BDNF to improve angiogenesis and cardiac function. J Surg Res 136:85–91. https://doi.org/10.1016/j.jss.2006.04.034

Liu X et al (2014) Elevated serum levels of FGF-2, NGF and IGF-1 in patients with manic episode of bipolar disorder. Psychiatry Res 218:54–60. https://doi.org/10.1016/j.psychres.2014.03.042

Messaoudi E, Ying SW, Kanhema T, Croll SD, Bramham CR (2002) Reduced plasma levels of NGF and BDNF in patients with manic episode of bipolar disorder. Psychiatry Res 108:450–464. https://doi.org/10.1111/j.1471-4159.2008.05781.x

Messaoudi E, Ying SW, Kanhema T, Croll SD, Bramham CR (2002) Reduced plasma levels of NGF and BDNF in patients with manic episode of bipolar disorder. Psychiatry Res 108:450–464. https://doi.org/10.1111/j.1471-4159.2008.05781.x

Messaoudi E, Ying SW, Kanhema T, Croll SD, Bramham CR (2002) Reduced plasma levels of NGF and BDNF in patients with manic episode of bipolar disorder. Psychiatry Res 108:450–464. https://doi.org/10.1111/j.1471-4159.2008.05781.x
Micer A, Lambiase A, Stampachiacchie B, Bonini S, Bonini S, Levi-Schaffer F (2007) Nerve growth factor and tissue repair remodeling: trkA (NGFR) and p75 (NTR), two receptors one fate. Cytokine Growth Factor Rev 18:245–256. https://doi.org/10.1016/j.cytofr.2007.04.004

Molendijk ML et al. (2011) Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 16:1088–1095. https://doi.org/10.1038/mp.2010.98

Mukherjee SP, Mukherjee C (1982) Similar activities of nerve growth factor and its homologue proinsulin in intracellular hydrogen peroxide production and metabolism in adipocytes. Transmembrane signalling relative to insulin-mimicking cellular effects. Biochem Pharmacol 31:3163–3172.

Munkholm K, Pedersen BK, Kessing LV, Vinberg M (2014) Elevated neurotrophic factor levels of plasma in the depressive affective temperaments: a cross-sectional study. European Journal of Pharmacology 722:89–93. https://doi.org/10.1016/j.ejphar.2014.03.025

Ng TB, Wong CM (1985) Epidermal and nerve growth factors manifest antipolypic and lipogenic activities in isolated rat adipocytes. Comp Biochem Physiol B 81:687–689.

Nico B, Mangieri D, Benagiano V, Crivellato E, Ribatti D (2008) Nerve growth factor as an angiogenic factor. Microvasc Res 75:135–141. https://doi.org/10.1016/j.mvr.2007.07.004

Otsuki K et al. (2008) Altered expression of neurotrophic factors in patients with major depression. J Psychiatr Res 42:1145–1153. https://doi.org/10.1016/j.jpsychires.2008.01.010

Pac CU, Marks DM, Han C, Patkar AA, Steffens D (2008) Does neurotrophin-3 have a therapeutic implication in major depression? Int J Neurosci 118:1515–1522. https://doi.org/10.1080/0000450802174589

Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ (1998) Transport of brain-derived neurotrophic factor across the blood–brain barrier. Neuropharmacology 37:1553–1561.

Pennaix BW, Beeckman AT, Honig A, Deeg DJ, Schoevers RA, van Eijk JT, van Tilburg W (2001) Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 58:221–227

Pikula A et al (2013) Serum brain-derived neurotrophic factor and vascular endothelial growth factor levels are associated with risk of stroke and vascular brain injury: Framingham Study. Stroke J Cereb Circ 44:2768–2775. https://doi.org/10.1161/strokeaha.113.001447

Poduslo JF, Curran GL (1996) Permeability at the blood–brain and blood–nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res 36:280–286

Prigent-Tessier A et al. (2013) Physical training and hypertension have opposite effects on endothelial brain-derived neurotrophic factor expression. Cardiovasc Res 100:374–382. https://doi.org/10.1093/cvr/cvt219

Proence CC, Song M, Lee FS (2016) Differential effects of BDNF and neurotrophin 4 (NT4) on endocytic sorting of TrkB receptors. J Neurochem 138:397–406. https://doi.org/10.1111/jnc.13676

Prunnsild P, Kazantseva A, Aid T, Palm K, Timmusk T (2007) Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics 90:397–406. https://doi.org/10.1016/j.ygeno.2007.05.004

Rihmer Z, Akisikal KK, Rihmer A, Akisikal HS (2010) Current research on affective temperaments. Curr Opin Psychiatry 23:12–18. https://doi.org/10.1097/YCO.Ob013e32833299d4

Rodrigue Fermeep M, Trinchero M, Minetto J, Beltran A, Fernandez BE (2009) Brain derived neurotrophic factor and neurotrophin-4 employ different intracellular pathways to modulate norepinephrine uptake and release in rat hypothalamus. Neuropeptides 43:275–282. https://doi.org/10.1016/j.npep.2009.06.001

Ross P, De Nicolio S, Carito V, Fiore M, Iannitelli A, Moreno S, Tirassa P (2017) Ocular nerve growth factor administration modulates brain-derived neurotrophic factor signaling in prefrontal cortex of healthy and diabetic rats. CNS Neurosci Therap 23:198–208. https://doi.org/10.1111/cns.12661

Roth CL, Elfers C, Gebhardt U, Muller HL, Reinher T (2013) Brain-derived neurotrophic factor and its relation to leptin in obese children before and after weight loss. Metabolism 62:226–234. https://doi.org/10.1016/j.metabol.2012.08.001

Salton SR (2003) Neurotrophins, growth-factor-regulated genes and the control of energy balance Mt. Sinai. J Med 70:93–100

Sariola H, Sainio K, Arumae U, Saarma M (1994) Neurotrophins and ciliary neurotrophic factor: their biology and pathology. Ann Med 26:355–363

Sasaki T et al. (2014) Developmental expression profiles of axon guidance signaling and the immune system in the marmoset cortex: potential molecular mechanisms of pruning of dendritic spines during primate synapse formation in late infancy and prepuberty (I). Biochem Biophys Res Commun 444:302–306. https://doi.org/10.1016/j.bbrc.2014.01.024

Sauer H, Wong V, Bjorklund A (1995) Brain-derived neurotrophic factor and neurotrophin-4/5 modify neurotransmitter-related gene expression in the 6-hydroxydopamine-lesioned rat striatum. Neuroscience 65:927–933

Schechteron LC, Bothwell M (1992) Novel roles for neurotrophins are suggested by BDNF and NT-3 mRNA expression in developing neurons. Neuron 9:449–463

Schedlowska M et al. (1993) Psychophysiological, neuroendocrine and cellular immune reactions under psychological stress. Neuropsychobiology 28:87–90. https://doi.org/10.1159/000119006

Schutte A, Yan Q, Mestres P, Giehl KM (2000) The endogenous survival promotion of axotomized rat corticospinal neurons by brain-derived neurotrophic factor is mediated via paracrine, rather than autocrine mechanisms. Neurosci Lett 290:185–188

Sen S, Duman R, Sanacora G (2008) Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 64:527–532. https://doi.org/10.1016/j.biopsych.2008.05.005

Shimizu E et al. (2003) Alterations of serum levels of brain-derived neurotrophic factor in depressed patients with or without antidepressants. Biol Psychiatry 59:449–463

Skaper SD (2008) The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurosid Drug Targets 7:46–62

Spitsbergen JM, Clemow DB, McCarty R, Steers WD, Tuttle JB (1998) Neurotrophins mediate hyperactive voiding in spontaneously hypertensive rats. Brain Res 790:151–159

Teng HK et al. (2005) ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J Neurosci 25:5455–5463. https://doi.org/10.1523/JNEURSCI.5123-04.2005

Tessarollo L, Tsoulfas P, Donovan MJ, Palko ME, Blair-Flynn J, Hempstead BL, Parada LF (1997) Targeted deletion of all isoforms of the trkC gene results in the absence of its ligand neurotrophin-3 in neuronal development and implicates trkC in normal cardiogenesis. Proc Natl Acad Sci USA 94:14776–14781

Tramontina JF, Andreazza AC, Kauer-Sant’anna M, Stertz L, Goi J, Chiarani F, Kapczinski F (2009) Brain-derived neurotrophic factor expression in the brain of patients with or without neurotrophic factor-deficient psychiatric disorders. J Psychiatr Res 43:983–989. https://doi.org/10.1016/j.jpsychires.2009.02.007

...
factor serum levels before and after treatment for acute mania. Neurosci Lett 452:111–113. https://doi.org/10.1016/j.neulet.2009.01.028
Tsai SJ (2017) Role of neurotrophic factors in attention deficit hyperactivity disorder. Cytokine Growth Factor Rev 34:35–41. https://doi.org/10.1016/j.cytogfr.2016.11.003
Tseng PT et al (2016) State-dependent increase in the levels of neurotrophin-3 and neurotrophin-4/5 in patients with bipolar disorder: a meta-analysis. J Psychiatr Res 79:86–92. https://doi.org/10.1016/j.jpsychires.2016.05.009
Tuttle JB, Spitsbergen JM, Stewart JS, McCarty RM, Steers WD (1995) Altered signalling in vascular smooth muscle from spontaneously hypertensive rats may link medial hypertrophy, vessel hyperinnervation and elevated nerve growth factor. Clin Exp Pharmacol Physiol Suppl 22:S117–S119
Villanueva R (2013) Neurobiology of major depressive disorder. Neural Plast 2013:873278. https://doi.org/10.1155/2013/873278
Walz JC et al (2009) Increased serum neurotrophin-4/5 levels in bipolar disorder. J Psychiatr Res 43:721–723. https://doi.org/10.1016/j.jpsychires.2008.10.005
Wan R, Weigand LA, Bateman R, Griffioen K, Mendelowitz D, Mattson MP (2014) Evidence that BDNF regulates heart rate by a mechanism involving increased brainstem parasympathetic neuron excitability. J Neurochem 129:573–580. https://doi.org/10.1111/jncc.12656
Wetmore C, Olson L (1995) Neuronal and nonneuronal expression of neurotrophins and their receptors in sensory and sympathetic ganglia suggest new intercellular trophic interactions. J Comp Neurol 353:143–159. https://doi.org/10.1002/cne.903530113
Wiener CD et al (2015) Serum levels of nerve growth factor (NGF) in patients with major depression disorder and suicide risk. J Affect Disord 184:245–248. https://doi.org/10.1016/j.jad.2015.05.067
Xiong P et al (2011) The role of NGF and IL-2 serum level in assisting the diagnosis in first episode schizophrenia. Psychiatry Res 189:72–76. https://doi.org/10.1016/j.psychres.2010.12.017
Yano H, Torkin R, Martin LA, Chao MV, Teng KK (2009) Proneurotrophin-3 is a neuronal apoptotic ligand: evidence for retrogradededirected cell killing. J Neurosci 29:14790–14802. https://doi.org/10.1523/JNEUROSCI.2059-09.2009
Yao Q, Song R, Ao L, Cleveland JC Jr, Fullerton DA, Meng X (2017) Neurotrophin 3 upregulates proliferation and collagen production in human aortic valve interstitial cells: a potential role in aortic valve sclerosis. Am J Physiol Cell Physiol 312:C697–C706. https://doi.org/10.1152/ajpcell.00292.2016
Yoshida T et al (2012) Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One 7:e42676. https://doi.org/10.1371/journal.pone.0042676
Youn JY, Wang T, Cai H (2009) An ezrin/calpain/P13K/AMPK/eNOSs1179 signaling cascade mediating VEGF-dependent endothelial nitric oxide production. Circ Res 104:50–59. https://doi.org/10.1161/CIRCRESAHA.108.178467
Zafra F, Hengerer B, Leibrock J, Thoenen H, Lindholm D (1990) Activity dependent regulation of BDNF and NGF mRNAs in the rat hippocampus is mediated by non-NMDA glutamate receptors. EMBO J 9:3545–3550
Zafra F, Castren E, Thoenen H, Lindholm D (1991) Interplay between glutamate and gamma-aminobutyric acid transmitter systems in the physiological regulation of brain-derived neurotrophic factor and nerve growth factor synthesis in hippocampal neurons. Proc Natl Acad Sci USA 88:10037–10041
Zagrebelsky M, Holz A, Dechant G, Barde YA, Bonhoeffer T, Korte M (2005) The p75 neurotrophin receptor negatively modulates dendrite complexity and spine density in hippocampal neurons. J Neurosci 25:9989–9999. https://doi.org/10.1523/JNEUR OSCI.2492-05.2005
Zettler C, Rush RA (1993) Elevated concentrations of nerve growth factor in heart and mesenteric arteries of spontaneously hypertensive rats. Brain Res 614:15–20
Zhang SH, Rush RA (2001) Neurotrophin 3 is increased in the spontaneously hypertensive rat. J Hypertens 19:2251–2256
Ziegenhorn AA et al (2007) Serum neurotrophins—a study on the time course and influencing factors in a large old age sample. Neurobiol Aging 28:1436–1445. https://doi.org/10.1016/j.neurobi aging.2006.06.011
Zoladz JA, Pilc A (2010) The effect of physical activity on the brain derived neurotrophic factor: from animal to human studies. J Physiol Pharmacol 61:533–541
Zucker IH, Patel KP, Schulz HD (2012) Neurohumoral stimulation. Heart Fail Clin 8:87–99. https://doi.org/10.1016/j. hfc.2011.08.007

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.